Table 4.
ASDAS-CRP and ASDAS-ESR from three consecutive assessments† (n = 201).
| T1 | T2 | T3 | p-value# | |||
|---|---|---|---|---|---|---|
| T1 versus T2 | T2 versus T3 | T1 versus T3 | ||||
| ASDAS-CRP | ||||||
| (Min, Max) | (0.1, 4.1) | (0.0, 4.7) | (0.1, 4.3) | 0.225 | 0.580 | 0.058 |
| Mean ± SD | 1.6 ± 0.8 | 1.5 ± 0.8 | 1.5 ± 0.8 | |||
| Median (P25, P75) | 1.5 (0.9, 2.1) | 1.3 (0.9, 1.9) | 1.4 (0.8, 1.9) | |||
| ASDAS-ESR | ||||||
| (Min, Max) | (0.3, 4.4) | (0.3, 4.2) | (0.4, 4.2) | 0.510 | 0.488 | 0.161 |
| Mean ± SD | 1.6 ± 0.8 | 1.5 ± 0.7 | 1.5 ± 0.7 | |||
| Median (P25, P75) | 1.4 (1.1, 2.0) | 1.5 (1.0, 2.0) | 1.4 (1.0, 1.9) | |||
Abbreviations: ASDAS Ankylosing Spondylitis Disease Activity Score, CRP C-reactive protein, ESR erythrocyte sedimentation rate, T time, SD standard deviation, P percentile.
†Comorbidities were identified within 1 year before the index date.
#Because the p-value of the normality test (Kolmogorov–Smirnov test) is < 0.05, the Wilcoxon Signed Rank test is used.
†Time of the three consecutive assessment: T1: the earliest time was considered the first time; T2: the second time was 84 ± 7 days; T3: the third time was 168 ± 7 days.